Led by Professor Patrick Forde of the Trinity St. James’s Cancer Institute (TSJCI) and the School of Medicine at Trinity College Dublin, this clinical trial represents the first investigation into the perioperative use of dual immune checkpoint inhibitors nivolumab and ipilimumab in patients with resectable diffuse pleural mesothelioma. Globally, mesothelioma affects approximately 30,000 individuals annually, with about 50 cases diagnosed each year in Ireland, highlighting the critical need for innovative therapeutic strategies beyond conventional surgery and chemotherapy.

The clinical conundrum with mesothelioma has long been the tumor’s infiltrative nature; it aggressively spreads along the pleural surfaces, making complete surgical resection exceedingly challenging, and thus limiting surgical cure rates. Immunotherapy, specifically agents targeting immune checkpoints PD-1 and CTLA-4, has revolutionized oncological treatments by enhancing the patient’s immune system to recognize and attack cancer cells, offering hope in advanced-stage mesothelioma. Nevertheless, until now, the utility of these agents in the neoadjuvant (pre-surgical) setting had remained unexplored.

Prof. Forde, a leading figure in immuno-oncology with a robust portfolio of lung cancer clinical trials, emphasized the innovative premise underlying this study: harnessing the immune system prior to surgical intervention could potentially improve not only the feasibility of surgery but also enhance long-term survival outcomes. By initiating checkpoint inhibitor treatment six weeks before surgery and continuing immunotherapy for up to one year postoperatively, the study tested the hypothesis that the immune system could be primed to eradicate microscopic residual disease and reduce recurrence rates.

The trial design involved randomizing patients to receive either monotherapy with nivolumab or combination immunotherapy with nivolumab plus ipilimumab. Remarkably, patients tolerated the treatment well, with low incidences of serious adverse events, and crucially, all were able to proceed safely to surgery. The safety profile observed here is particularly consequential, as concerns about potential immunotherapy-induced perioperative complications have historically impeded neoadjuvant exploration in mesothelioma.

Follow-up analyses revealed that those receiving combination immunotherapy exhibited survival benefits exceeding historical controls from prior mesothelioma trials devoid of immunotherapeutic intervention. While these results are preliminary given the early phase and limited patient numbers, they portend a meaningful clinical impact and set the stage for subsequent larger scale, randomized trials that could validate and potentially establish new therapeutic standards.

In a significant scientific collaboration with Johns Hopkins University, the research team also delved into the emerging field of circulating tumor DNA (ctDNA) surveillance. By sequencing ctDNA from patients’ blood samples drawn before and during treatment, investigators sought to identify molecular biomarkers predictive of therapeutic response. Their findings suggest that dynamic monitoring of tumor-derived genetic fragments in circulation not only forecasts the likelihood of successful surgical outcomes but also signals the potential risk of relapse. This represents a paradigm shift toward personalized treatment algorithms wherein real-time molecular monitoring complements clinical decision-making.

Professor Forde expressed cautious optimism about these findings, underscoring the translational significance of combining immunotherapy with surgery and molecular diagnostics. “Our research illuminates a new frontier in early mesothelioma treatment, leveraging the patient’s immune system at the earliest possible juncture to augment tumor eradication and improve survival,” he stated. “TSJCI continues to spearhead cutting-edge clinical trials, aiming to broaden patient access to innovative therapies and translate basic immunologic insights into tangible clinical benefits.”

This research also highlights the strategic importance of Ireland’s Trinity St. James’s Cancer Institute, the nation’s first internationally accredited Comprehensive Cancer Centre, which since 2024 has been under Prof. Forde’s leadership as Prendergast Professor of Immuno-Oncology. The institute’s mission to intertwine advanced clinical research with community-based care infrastructure has enabled rapid deployment and evaluation of novel interventions in diverse cancer populations across Ireland and Europe.

Mesothelioma poses unique challenges including limited early detection tools, intrinsic resistance to standard therapies, and a historically grim prognosis. The emergence of immunotherapy has begun to challenge these entrenched obstacles, with the combined modality approach underscored by this trial representing a critical evolution. By administering checkpoint inhibitors in the perioperative window, the immune system is activated to detect and eliminate tumor cells not only at the primary site but also potentially at distant micrometastatic niches.

Moreover, the integration of ctDNA analyses introduces an exciting dimension of precision oncology, enabling clinicians to tailor treatment intensity and duration based on molecular responses rather than purely radiographic or clinical parameters. This could substantially reduce overtreatment risks while maximizing efficacy, fostering a shift toward adaptive immunotherapy paradigms.

The phase 2 trial’s insights extend beyond mesothelioma, offering a conceptual framework that might be extrapolated to other thoracic malignancies and solid tumors treated surgically. The notion of “immune priming” before cytoreductive interventions is gaining momentum, supported by accumulating evidence that neoadjuvant immunotherapy can reshape the tumor microenvironment to facilitate immune cell infiltration, improve antigen presentation, and perhaps induce long-lasting systemic anti-tumor immunity.

Nonetheless, challenges remain. Larger confirmatory studies will be essential to establish statistical significance, optimize dosage and timing regimens, and define patient subgroups most likely to benefit. Long-term monitoring is also needed to assess durability of response and potential late toxicities inherent to immune checkpoint blockade. Furthermore, the mechanistic underpinnings of immunotherapy synergy with surgery require deeper exploration, including the role of tumor mutational burden, immune cell repertoire changes, and stromal remodeling.

As research efforts progress, interdisciplinary collaboration between oncologists, immunologists, thoracic surgeons, and molecular biologists will be crucial to unlock the full potential of combination treatments. Equally, expanding patient access to such trials through centralized cancer centers and international cooperation remains a global priority.

In sum, this seminal trial offers a beacon of hope for mesothelioma patients who previously faced limited therapeutic options and poor survival odds. By strategically integrating immune checkpoint inhibitors in the preoperative setting and leveraging cutting-edge molecular diagnostics, the study pioneers a novel approach that could transform clinical practice. The oncology community eagerly anticipates subsequent data releases and hopes this innovative paradigm will serve as a catalyst for accelerating the integration of immunotherapy across surgical oncology.

Subject of Research: People

Article Title: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

News Publication Date: 8-Sep-2025

Diffuse pleural mesothelioma is a rare malignancy arising from the mesothelial cells lining the pleura—the protective membrane enveloping the lungs. Globally, approximately 30,000 new cases emerge annually, the vast majority linked to prior asbestos exposure. The disease’s diffuse and infiltrative nature makes it uniquely challenging, often resisting conventional modalities such as surgery, chemotherapy, and radiation therapy. Unlike typical solid tumors, mesotheliomas rarely manifest as discrete masses. Instead, their growth is characterized by a diffuse spreading pattern along the pleural surface, causing difficulties in precise tumor quantification and response assessment using standard imaging techniques.

The clinical trial spearheaded by Dr. Reuss began during his fellowship at the Johns Hopkins Kimmel Cancer Center, where much of the research was conducted. This phase II study evaluated the perioperative administration of nivolumab, a PD-1 immune checkpoint inhibitor, alone or in combination with ipilimumab, a CTLA-4 inhibitor, in patients with surgically resectable diffuse pleural mesothelioma. The main goal was to test the feasibility and safety of neoadjuvant (preoperative) immunotherapy, as well as its integration with subsequent surgical interventions.

Immunotherapy has revolutionized the treatment of various solid tumors by harnessing the body’s immune system to recognize and destroy cancer cells. However, its role in mesothelioma remains understudied and controversial. Prior large-scale trials incorporating surgery with systemic therapies failed to demonstrate consistent survival benefits, casting doubt on the utility of surgical resection. This study challenges that paradigm by incorporating immune checkpoint blockade in a strategic perioperative timeline, attempting to augment antitumor immunity when tumor burden is minimized.

One of the study’s most innovative features lies in its use of circulating tumor DNA (ctDNA) profiling. ctDNA refers to fragments of tumor-derived genetic material released into the bloodstream, offering a minimally invasive biomarker for real-time disease monitoring. Mesothelioma’s low mutational burden complicates traditional ctDNA detection, but the researchers applied an ultra-sensitive genome-wide sequencing approach. This technique enabled the detection of microscopic residual disease that imaging alone could not reveal, providing unprecedented insight into tumor dynamics at a molecular level.

The ability to monitor ctDNA kinetics longitudinally, especially in the perioperative period, may redefine how clinicians assess treatment response. A decrease or absence of ctDNA post-immunotherapy was correlated with better outcomes, while persistence suggested early relapse or treatment resistance. This molecular surveillance could soon guide therapeutic decision-making, tailoring interventions more precisely and potentially sparing patients from ineffective treatments.

Despite these promising findings, the investigators are cautious. Phase II trials primarily assess feasibility, safety, and biological signals rather than definitive clinical efficacy. While both arms of the trial displayed encouraging improvements in progression-free and overall survival, larger randomized studies are necessary to confirm these benefits and elucidate long-term outcomes. This cautious optimism underscores the complexity of mesothelioma and the need for rigorous validation before widespread clinical adoption.

The implications of this research extend beyond just surgical candidacy assessment. By integrating immunotherapy with innovative diagnostic tools, the study illuminates pathways for personalized medicine in a cancer type historically treated with a one-size-fits-all approach. The novel perioperative immunotherapeutic strategy could fundamentally alter the treatment algorithm, shifting the balance toward more individualized and effective interventions.

From a biological standpoint, the diffuse growth pattern of pleural mesothelioma complicates conventional imaging-based response assessments. Tumors often spread thinly along the pleural surfaces, eluding volumetric measurement and confounding radiographic evaluation. The study’s use of ctDNA addresses this limitation, offering a molecular snapshot of tumor presence and burden that complements traditional methods.

The research was supported by a constellation of institutional and governmental grants, with Bristol Myers Squibb sponsoring the clinical trial. Collaborations spanned multiple leading academic cancer centers, reflecting the multidisciplinary effort required to tackle mesothelioma. This collective endeavor highlights the importance of integrating clinical oncology, molecular biology, and bioinformatics to advance cancer therapeutics.

Throughout his commentary on these findings, Dr. Reuss emphasized the potential transformative impact of perioperative immunotherapy but tempered expectations by recognizing the need for continued investigation. “Our study opens windows of opportunity and lays the groundwork for future research to develop better therapies,” he remarked. The road ahead involves larger trials, refinement of ctDNA methodologies, and exploration of combination regimens that can maximize patient outcomes.

In sum, this phase II trial signals an exciting chapter in mesothelioma research, positioning immunotherapy as a pivotal component in the perioperative management of operable diffuse pleural mesothelioma. The integration of cutting-edge molecular diagnostics with innovative treatment strategies paves the way for personalized care models in this challenging disease arena. While the journey toward definitive cure or long-term remission remains arduous, these advances represent critical steps forward, inspiring hope for patients and clinicians alike.

Subject of Research: Diffuse pleural mesothelioma, perioperative immunotherapy, circulating tumor DNA (ctDNA) analyses

Article Title: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: phase 2 trial results and ctDNA analyses

News Publication Date: September 8, 2025

Web References:

• Nature Medicine Article DOI

References:

• Clinical trial presented at the 2025 World Conference on Lung Cancer, Barcelona, Spain
• Published manuscript in Nature Medicine

Keywords: Cancer, Clinical studies, Diffuse pleural mesothelioma, Immunotherapy, Nivolumab, Ipilimumab, Circulating tumor DNA, ctDNA, Perioperative treatment, Surgical oncology